NEW YORK (GenomeWeb News) — Genomic Health said today it has hired Medical Solutions to exclusively distribute its Oncotype DX breast cancer assay in the UK.
Chu Chang, vice president of business development at Genomic Health, said the agreement with the UK diagnostics and healthcare company is part of Genomic Health's strategy to broaden access to its test to patients outside of the US.
The Oncotype test predicts the likelihood of breast cancer recurrence in women with newly diagnosed, early stage invasive breast cancer. It also predicts the chance that chemotherapy will benefit “a large portion” of patients with early-stage breast cancer, the company said.
Genomic Health said it has service and supply agreements for the Oncotype in Israel and Japan. In the US the test is performed by CLIA-certified labs.